General Pharmacology — MCQs

General Pharmacology Indian Medical PG Practice Questions and MCQs

Question 281: Which of the following statements about non-competitive antagonism is FALSE?

A. The dose-response curve flattens.
B. The antagonism is irreversible.
C. Potency remains the same.
D. Efficacy remains the same. (Correct Answer)

Explanation: In **non-competitive antagonism**, the antagonist binds to an allosteric site (different from the agonist’s binding site) [2] or binds irreversibly to the active site [1]. This prevents the agonist from producing a maximal effect, regardless of how much agonist concentration is increased [1]. In non-competitive antagonism, the **efficacy (Emax) decreases** [1]. Because the antagonist effectively "removes" functional receptors from the system or prevents the agonist from activating them, the maximum possible response of the drug is reduced [1]. Therefore, the statement "Efficacy remains the same" is false. As the maximal response (Emax) decreases, the height of the log dose-response curve (LDRC) drops, leading to a characteristic "flattening" of the curve [1]. While not all non-competitive antagonists are irreversible, most irreversible antagonists (like Phenoxybenzamine) function non-competitively because they cannot be displaced by increasing agonist concentrations [1]. In pure non-competitive antagonism, the **EC50 (potency)** typically remains unchanged because the remaining functional receptors still have the same affinity for the agonist [1].

Question 282: A patient was prescribed a first-generation H1 antihistamine. What should they be advised to avoid?

A. Driving motor vehicles (Correct Answer)
B. Consuming processed cheese
C. Strenuous physical exertion
D. All of the above

Explanation: **Explanation:** **1. Why Option A is Correct:** First-generation H1 antihistamines (e.g., Diphenhydramine, Chlorpheniramine, Promethazine) are highly **lipophilic** and readily cross the **blood-brain barrier (BBB)**. Once in the CNS, they block H1 receptors involved in maintaining wakefulness and alertness. This leads to significant **sedation, drowsiness, and psychomotor impairment**. Patients are strictly advised to avoid driving or operating heavy machinery because their reaction time and coordination are compromised, increasing the risk of accidents. **2. Why Other Options are Incorrect:** * **Option B (Processed cheese):** Avoiding tyramine-rich foods like processed cheese is a specific precaution for patients on **MAO inhibitors** (to prevent a hypertensive "cheese reaction"), not antihistamines. * **Option C (Strenuous physical exertion):** While some drugs (like Statins or certain Beta-blockers) might require caution during exercise, first-generation antihistamines do not have a direct contraindication with physical exertion, though the accompanying drowsiness might make it difficult. **3. NEET-PG High-Yield Pearls:** * **Second-generation H1 blockers** (e.g., Cetirizine, Loratadine, Fexofenadine) are preferred for active patients because they have low lipid solubility, do not cross the BBB easily, and are **non-sedating**. * **Fexofenadine** is considered the least sedating as it is a substrate for the P-glycoprotein efflux pump. * **Anticholinergic side effects:** First-generation H1 blockers also block muscarinic receptors, leading to dry mouth, blurred vision, and urinary retention. * **Teratogenicity:** Chlorpheniramine is generally considered the safest antihistamine during pregnancy.

Question 283: What is a counterfeit drug?

A. A fake medicine
B. A medicine containing the wrong ingredient
C. A medicine with the active ingredient in the wrong dose
D. All the above (Correct Answer)

Explanation: ### Explanation **Conceptual Understanding** According to the World Health Organization (WHO), **counterfeit drugs** (or Substandard and Falsified medical products) are medicines that are deliberately and fraudulently mislabeled with respect to identity and/or source. The core concept is **deception**. A counterfeit drug is not just a "fake" pill; it encompasses any product where the manufacturing, composition, or branding is intentionally misrepresented to mimic a genuine product. **Why "All the Above" is Correct:** * **Option A (Fake medicine):** This refers to products that contain no active pharmaceutical ingredient (API) at all (e.g., a pill made only of starch or chalk). * **Option B (Wrong ingredient):** To reduce costs or mimic effects, counterfeiters may substitute the expensive API with a cheaper, different, or even toxic chemical (e.g., using diethylene glycol instead of glycerin). * **Option C (Wrong dose):** A drug may contain the correct API but in an incorrect strength—either too low (sub-therapeutic), which leads to treatment failure and antimicrobial resistance, or too high, which leads to toxicity. **High-Yield Clinical Pearls for NEET-PG:** * **Spurious Drugs:** In the Indian context (Drugs and Cosmetics Act), counterfeit drugs are often legally classified as "Spurious." * **Public Health Impact:** The most common counterfeit drugs globally are **Antimalarials** and **Antibiotics**. * **Identification:** Counterfeit drugs are identified through forensic tools like **Raman Spectroscopy** or by checking for inconsistencies in packaging, batch numbers, and holograms. * **Dangers:** They are a major cause of **antimicrobial resistance (AMR)** due to sub-therapeutic dosing and can lead to mass poisoning (e.g., renal failure from contaminated syrups).

Question 284: Which of the following drugs does NOT cause pyridoxine deficiency?

A. Hydralazine
B. Griseofulvin (Correct Answer)
C. Cycloserine
D. Penicillamine

Explanation: **Explanation:** The correct answer is **Griseofulvin**. Pyridoxine (Vitamin B6) deficiency is a common side effect of drugs that interfere with its metabolism or increase its excretion, often leading to peripheral neuropathy. **1. Why Griseofulvin is the correct answer:** Griseofulvin is an antifungal drug used for dermatophytosis. Its primary mechanism involves binding to fungal microtubules and inhibiting mitosis. It does not interfere with pyridoxine metabolism. Its notable side effects include headache, GI upset, and photosensitivity, but not peripheral neuropathy via B6 deficiency. **2. Why the other options are incorrect:** The following drugs are classic causes of pyridoxine deficiency through various mechanisms: * **Hydralazine:** This vasodilator reacts with pyridoxal phosphate to form a hydrazone complex, which is then excreted, leading to depletion. * **Cycloserine:** An antitubercular drug that acts as a structural analogue of D-alanine; it inhibits the enzymes that require pyridoxal phosphate as a cofactor. * **Penicillamine:** Used in Wilson’s disease and rheumatoid arthritis, it binds to pyridoxal phosphate, rendering it inactive and increasing its renal clearance. **High-Yield Clinical Pearls for NEET-PG:** * **Isoniazid (INH):** The most frequently tested drug causing B6 deficiency. It inhibits pyridoxine kinase and forms a complex with B6. Always co-prescribe 10–50 mg of Pyridoxine with INH. * **Clinical Presentation:** Deficiency typically manifests as **peripheral neuropathy** (paresthesia in a glove-and-stocking distribution), sideroblastic anemia, and seizures. * **Mnemonic (HICP):** **H**ydralazine, **I**soniazid, **C**ycloserine, **P**enicillamine are the "Big Four" causes of drug-induced B6 deficiency.

Question 285: Which of the following parameters signifies the effective drug removal from the body?

A. Clearance (Correct Answer)
B. Bioavailability
C. Safety
D. Volume of distribution

Explanation: **Explanation:** **1. Why Clearance is Correct:** **Clearance (Cl)** is defined as the volume of plasma from which a drug is completely removed per unit of time (e.g., ml/min). It is the most important parameter for determining the **maintenance dose** of a drug. While metabolism and excretion are the processes involved, clearance is the quantitative measure that signifies the efficiency of drug removal from the body. It is calculated using the formula: $Cl = \text{Rate of elimination} / \text{Plasma concentration}$. **2. Why Other Options are Incorrect:** * **Bioavailability (B):** This refers to the fraction of an administered dose of unchanged drug that reaches the systemic circulation. it is a measure of **absorption**, not removal. * **Safety:** This is a clinical profile of a drug (often measured by the Therapeutic Index) rather than a pharmacokinetic parameter that quantifies drug removal. * **Volume of Distribution (Vd):** This is a theoretical volume that relates the amount of drug in the body to its plasma concentration. It signifies drug **distribution** and sequestration in tissues, not its removal. **3. NEET-PG High-Yield Clinical Pearls:** * **First-Order Kinetics:** Most drugs follow this, where a constant *fraction* of drug is cleared per unit time (Clearance remains constant). * **Zero-Order Kinetics:** A constant *amount* of drug is cleared (e.g., Alcohol, Phenytoin, Aspirin). Here, clearance decreases as plasma concentration increases. * **Half-life ($t_{1/2}$):** It is inversely proportional to clearance ($t_{1/2} = 0.693 \times Vd / Cl$). If clearance decreases (e.g., renal failure), the half-life increases. * **Steady State:** It takes approximately **4 to 5 half-lives** to reach a steady-state concentration when a drug is given at a constant rate.

Question 286: Tacrolimus belongs to which class of drug?

A. Calcineurin inhibitor (Correct Answer)
B. mTOR inhibitor
C. Hypoxanthine inhibitor
D. Inosine inhibitor

Explanation: **Explanation:** **Tacrolimus** is a potent immunosuppressant primarily used to prevent organ transplant rejection. It belongs to the **Calcineurin Inhibitor (CNI)** class. 1. **Mechanism of Action (Why A is correct):** Tacrolimus binds to an intracellular protein called **FKBP-12** (FK-binding protein). This complex then inhibits **calcineurin**, a phosphatase responsible for dephosphorylating the "Nuclear Factor of Activated T-cells" (NFAT). Without dephosphorylation, NFAT cannot enter the nucleus to promote the transcription of **Interleukin-2 (IL-2)**, thereby inhibiting T-cell activation and proliferation. 2. **Analysis of Incorrect Options:** * **B. mTOR Inhibitors:** Drugs like **Sirolimus** (Rapamycin) and Everolimus belong here. They also bind to FKBP-12 but inhibit the "mammalian Target of Rapamycin" (mTOR) pathway instead of calcineurin. * **C. Hypoxanthine Inhibitors:** This is not a standard pharmacological classification for immunosuppressants, though drugs like Azathioprine interfere with purine (hypoxanthine/guanine) synthesis. * **D. Inosine Inhibitors:** **Mycophenolate Mofetil** inhibits Inosine Monophosphate Dehydrogenase (IMPDH), an enzyme essential for *de novo* guanosine nucleotide synthesis in lymphocytes. **High-Yield Clinical Pearls for NEET-PG:** * **Comparison:** Tacrolimus is ~100 times more potent than Cyclosporine (which binds to Cyclophilin, not FKBP-12). * **Side Effects:** Nephrotoxicity (most common), Neurotoxicity (tremors/seizures), and **Post-transplant Diabetes Mellitus (PTDM)**. * **Key Distinction:** Unlike Cyclosporine, Tacrolimus does **not** typically cause hirsutism or gum hyperplasia. * **Drug Interactions:** Metabolized by **CYP3A4**; levels are increased by grapefruit juice and macrolides.

Question 287: Which of the following antihypertensive agents is a prodrug that is converted to its active form in the brain?

A. Doxazosin
B. Methyldopa (Correct Answer)
C. Clonidine
D. Nitroprusside

Explanation: **Explanation:** **Methyldopa** is a centrally acting antihypertensive agent and a classic example of a **prodrug**. It crosses the blood-brain barrier via an aromatic amino acid transporter. Once in the brain, it undergoes a two-step enzymatic conversion: first by *DOPA decarboxylase* to alpha-methyldopamine, and then by *dopamine beta-hydroxylase* to its active metabolite, **alpha-methylnorepinephrine**. This active form stimulates central **alpha-2 adrenergic receptors** in the nucleus tractus solitarius, leading to a decrease in sympathetic outflow and a subsequent fall in blood pressure. **Analysis of Incorrect Options:** * **A. Doxazosin:** This is a selective **alpha-1 blocker** that acts peripherally on vascular smooth muscle to cause vasodilation. It is not a prodrug and does not require central activation. * **C. Clonidine:** While it is also a centrally acting alpha-2 agonist, it is **not a prodrug**. It is active in its parent form and directly stimulates the receptors upon crossing the blood-brain barrier. * **D. Nitroprusside:** This is a direct-acting parenteral vasodilator used in hypertensive emergencies. It acts by releasing nitric oxide (NO) directly into the systemic circulation, not via central nervous system activation. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Methyldopa remains a preferred agent for managing **hypertension in pregnancy** (along with Labetalol and Hydralazine). * **Adverse Effects:** A classic side effect is a **positive Coomb’s test**, which can rarely lead to autoimmune hemolytic anemia. It can also cause hyperprolactinemia and sedation. * **Mechanism Tip:** Remember that Methyldopa acts as a "false neurotransmitter" precursor.

Question 288: Therapeutic drug monitoring is required for all drugs except:

A. Phenytoin
B. Metformin (Correct Answer)
C. Tacrolimus
D. Cyclosporin

Explanation: **Explanation:** Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring drug concentrations in the blood to maintain a constant concentration within a specific **narrow therapeutic window**. **Why Metformin is the correct answer:** Metformin is a biguanide used for Type 2 Diabetes. It has a **wide therapeutic index**, meaning the margin between the effective dose and the toxic dose is large. More importantly, the clinical effect of Metformin (blood glucose levels and HbA1c) is easily measurable and serves as a reliable pharmacodynamic marker. Therefore, monitoring the drug's plasma concentration is unnecessary; we monitor the patient's response instead. **Why the other options are incorrect:** * **Phenytoin:** This antiepileptic follows **zero-order (capacity-limited) kinetics** at therapeutic doses. Small dose increases can lead to disproportionately large increases in plasma levels, causing toxicity (nystagmus, ataxia). TDM is mandatory. * **Tacrolimus & Cyclosporin:** These are calcineurin inhibitors used in organ transplantation. They have a **narrow therapeutic window** and high inter-individual pharmacokinetic variability. Sub-therapeutic levels lead to graft rejection, while high levels cause nephrotoxicity. Monitoring "trough levels" is standard clinical practice. **High-Yield Clinical Pearls for NEET-PG:** * **Indications for TDM:** Narrow therapeutic index, non-linear kinetics, lack of easily measurable physiological markers, and suspected toxicity or non-compliance. * **Drugs requiring TDM (Mnemonic: "The Lithium Digs Low"):** **The**ophylline, **Lithium**, **Dig**oxin, **S**alicylates (high dose), **L**evodopa, **A**minoglycosides, **W**arfarin (though PT/INR is used), and Antiepileptics (Phenytoin, Carbamazepine). * **Drugs NOT requiring TDM:** Antihypertensives (monitor BP), Hypoglycemics (monitor Glucose), and Oral Anticoagulants (monitor PT/INR).

Question 289: Who is considered the father of modern pharmacology?

A. Ram Nath Chopra
B. Oswald Schmiedeberg (Correct Answer)
C. David Sackett
D. Paul Ehrlich

Explanation: **Explanation:** **Oswald Schmiedeberg (Option B)** is recognized as the **Father of Modern Pharmacology**. He played a pivotal role in transforming pharmacology from a descriptive branch of materia medica into a rigorous experimental science. He established the first institute of pharmacology at the University of Strasbourg and founded the first pharmacological journal. His work focused on the relationship between the chemical structure of substances and their biological effects, laying the foundation for modern drug research. **Analysis of Incorrect Options:** * **Ram Nath Chopra (Option A):** Known as the **Father of Indian Pharmacology**. He was instrumental in establishing pharmacological research in India and documented the medicinal properties of indigenous Indian plants. * **David Sackett (Option C):** Known as the **Father of Evidence-Based Medicine (EBM)**. His work focused on clinical epidemiology and integrating clinical expertise with the best available external clinical evidence. * **Paul Ehrlich (Option D):** Known as the **Father of Chemotherapy**. He proposed the "side-chain theory" (receptor concept) and developed Salvarsan (the "magic bullet") for the treatment of syphilis. **High-Yield Facts for NEET-PG:** * **Rudolf Buchheim:** Established the first laboratory for experimental pharmacology (predecessor to Schmiedeberg). * **S.N. Pradhan:** Often associated with early psychopharmacology research in India. * **Receptor Concept:** While Schmiedeberg professionalized the field, **John Newport Langley** and **Paul Ehrlich** are credited with the conceptualization of drug receptors. * **Pharmacodynamics vs. Pharmacokinetics:** Remember that Schmiedeberg’s era marked the shift toward understanding *what the drug does to the body* (Pharmacodynamics) through experimental methods.

Question 290: Which of the following effects is NOT caused by Platelet Activating Factor (PAF)?

A. Bronchoconstriction
B. Vasoconstriction
C. Decreased vascular permeability (Correct Answer)
D. Vasodilation

Explanation: **Explanation:** Platelet Activating Factor (PAF) is a potent phospholipid autacoid derived from cell membranes. It plays a crucial role in inflammation, allergy, and anaphylaxis. **Why Option C is the correct answer:** PAF is one of the most potent agents known to **increase vascular permeability**. It causes the contraction of endothelial cells, leading to the formation of intercellular gaps. This results in the leakage of plasma proteins and fluid into the extravascular space (edema). Therefore, "Decreased vascular permeability" is the incorrect effect and the right answer to this question. **Analysis of Incorrect Options:** * **A. Bronchoconstriction:** PAF is a powerful bronchoconstrictor (about 1000 times more potent than histamine). It also induces bronchial hyperreactivity, a hallmark of asthma. * **B & D. Vasoconstriction and Vasodilation:** PAF has complex vascular effects. While it is a potent **vasodilator** in most vascular beds (leading to hypotension and shock), it can cause **vasoconstriction** in specific areas, such as the pulmonary and coronary arteries, depending on the dose and the underlying vascular tone. **High-Yield Clinical Pearls for NEET-PG:** * **Source:** Produced by platelets, neutrophils, monocytes, and endothelial cells via the action of Phospholipase A2. * **Potency:** It is significantly more potent than histamine in inducing wheal and flare reactions. * **Platelet Effects:** As the name suggests, it causes platelet aggregation and release of thromboxane A2. * **Antagonist:** **Ginkgolide B** (derived from the Ginkgo biloba tree) is a specific PAF receptor antagonist often mentioned in competitive exams.

Practice by Chapter

Pharmacokinetics: Absorption and Distribution

Practice Questions

Pharmacokinetics: Metabolism and Excretion

Practice Questions

Pharmacodynamics and Receptor Theory

Practice Questions

Drug-Receptor Interactions and Dose-Response

Practice Questions

Pharmacogenetics and Personalized Medicine

Practice Questions

Adverse Drug Reactions and Toxicity

Practice Questions

Drug Interactions

Practice Questions

Drug Development and Regulation

Practice Questions

Pediatric and Geriatric Pharmacology

Practice Questions

Placental Transfer and Lactation

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free